Biomea Fusion Files 8-K Report
Ticker: BMEA · Form: 8-K · Filed: Mar 7, 2024 · CIK: 1840439
| Field | Detail |
|---|---|
| Company | Biomea Fusion, Inc. (BMEA) |
| Form Type | 8-K |
| Filed Date | Mar 7, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Biomea Fusion filed an 8-K, likely containing important updates for investors.
AI Summary
On March 6, 2024, Biomea Fusion, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Redwood City, California.
Why It Matters
This 8-K filing indicates that Biomea Fusion, Inc. is providing updates or submitting required documentation to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a high-risk situation.
Key Players & Entities
- Biomea Fusion, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Redwood City, CA (location) — Principal Executive Offices
- March 6, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Biomea Fusion, Inc.?
The 8-K filing is primarily for 'Other Events' and 'Financial Statements and Exhibits', indicating updates or submissions of required documentation to the SEC.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 6, 2024.
Where are Biomea Fusion, Inc.'s principal executive offices located?
Biomea Fusion, Inc.'s principal executive offices are located at 900 Middlefield Road, 4th Floor, Redwood City, CA 94063.
In which state is Biomea Fusion, Inc. incorporated?
Biomea Fusion, Inc. is incorporated in Delaware.
What is the SIC code for Biomea Fusion, Inc.?
The Standard Industrial Classification (SIC) code for Biomea Fusion, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,080 words · 4 min read · ~4 pages · Grade level 14.2 · Accepted 2024-03-07 16:02:04
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value BMEA The Nasdaq Global Se
Filing Documents
- d802391d8k.htm (8-K) — 33KB
- d802391dex991.htm (EX-99.1) — 34KB
- d802391dex992.htm (EX-99.2) — 7KB
- d802391dex993.htm (EX-99.3) — 7KB
- d802391dex994.htm (EX-99.4) — 6KB
- g802391ex99_2p1g1.jpg (GRAPHIC) — 634KB
- g802391ex99_3p1g1.jpg (GRAPHIC) — 672KB
- g802391ex99_4p1g1.jpg (GRAPHIC) — 588KB
- 0001193125-24-062154.txt ( ) — 2843KB
- bmea-20240306.xsd (EX-101.SCH) — 3KB
- bmea-20240306_lab.xml (EX-101.LAB) — 18KB
- bmea-20240306_pre.xml (EX-101.PRE) — 11KB
- d802391d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release titled, "Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function." 99.2 Poster presentation titled, "Durable Glycemic Control With BMF-219 During Off-Treatment Period at Week 26: a Phase 1/2 Trial of BMF-219 in Patients with Type 2 Diabetes (Covalent-111)." 99.3 Poster presentation titled, "Key Observations from the Dose-Escalation Portion of Covalent-111, a Phase 1/2 Trial of the Covalent Menin Inhibitor BMF-219 in Patients with Type 2 Diabetes." 99.4 Poster presentation titled, "Case Studies from Covalent-111, a Phase 1/2 Trial Of BMF-219, a Covalent Menin Inhibitor, in Patients with Type 2 Diabetes." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BIOMEA FUSION, INC. Date: March 7, 2024 By: /s/ Thomas Butler Thomas Butler Principal Executive Officer